Acorda Therapeutics and FDA Reach Agreement on Special Protocol ...
Business Wire (press release) - San Francisco,CA,USA
The design of MS-F204 is fundamentally similar to Acorda’s first Phase 3 trial of Fampridine-SR in MS, MS-F203. However, the current study protocol will ...
See all stories on this topic